PMV Pharmaceuticals (PMVP) Competitors $1.52 +0.10 (+7.04%) Closing price 04:00 PM EasternExtended Trading$1.52 -0.01 (-0.33%) As of 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMVP vs. OCGN, ALDX, BNTC, TNXP, CRVS, FHTX, TLSA, ESPR, SCPH, and ANNXShould you be buying PMV Pharmaceuticals stock or one of its competitors? The main competitors of PMV Pharmaceuticals include Ocugen (OCGN), Aldeyra Therapeutics (ALDX), Benitec Biopharma (BNTC), Tonix Pharmaceuticals (TNXP), Corvus Pharmaceuticals (CRVS), Foghorn Therapeutics (FHTX), Tiziana Life Sciences (TLSA), Esperion Therapeutics (ESPR), scPharmaceuticals (SCPH), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry. PMV Pharmaceuticals vs. Its Competitors Ocugen Aldeyra Therapeutics Benitec Biopharma Tonix Pharmaceuticals Corvus Pharmaceuticals Foghorn Therapeutics Tiziana Life Sciences Esperion Therapeutics scPharmaceuticals Annexon PMV Pharmaceuticals (NASDAQ:PMVP) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk. Do analysts prefer PMVP or OCGN? PMV Pharmaceuticals currently has a consensus target price of $5.50, indicating a potential upside of 261.84%. Ocugen has a consensus target price of $6.00, indicating a potential upside of 482.52%. Given Ocugen's higher probable upside, analysts plainly believe Ocugen is more favorable than PMV Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMV Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Ocugen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, PMVP or OCGN? PMV Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.84, meaning that its share price is 284% more volatile than the S&P 500. Is PMVP or OCGN more profitable? PMV Pharmaceuticals has a net margin of 0.00% compared to Ocugen's net margin of -1,197.71%. PMV Pharmaceuticals' return on equity of -47.94% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets PMV PharmaceuticalsN/A -47.94% -43.82% Ocugen -1,197.71%-255.25%-86.79% Which has preferable valuation & earnings, PMVP or OCGN? Ocugen has higher revenue and earnings than PMV Pharmaceuticals. Ocugen is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPMV PharmaceuticalsN/AN/A-$58.71M-$1.57-0.97Ocugen$4.05M74.34-$54.05M-$0.20-5.15 Do institutionals & insiders have more ownership in PMVP or OCGN? 90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 7.6% of PMV Pharmaceuticals shares are held by company insiders. Comparatively, 4.4% of Ocugen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer PMVP or OCGN? In the previous week, Ocugen had 9 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 14 mentions for Ocugen and 5 mentions for PMV Pharmaceuticals. Ocugen's average media sentiment score of 0.98 beat PMV Pharmaceuticals' score of -0.23 indicating that Ocugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PMV Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocugen 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryOcugen beats PMV Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get PMV Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PMVP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMVP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMVP vs. The Competition Export to ExcelMetricPMV PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$75.25M$2.44B$5.55B$9.83BDividend YieldN/A1.78%4.62%4.11%P/E Ratio-0.975.3321.9425.46Price / SalesN/A725.14460.58105.19Price / CashN/A183.0237.7558.93Price / Book0.574.708.476.06Net Income-$58.71M$31.61M$3.26B$265.11M7 Day PerformanceN/A2.95%3.56%2.90%1 Month Performance20.63%4.27%5.97%3.99%1 Year Performance2.70%7.66%42.70%26.92% PMV Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMVPPMV Pharmaceuticals3.1146 of 5 stars$1.52+7.0%$5.50+261.8%-4.7%$75.25MN/A-0.9750Earnings ReportGap UpOCGNOcugen1.8055 of 5 stars$1.00+0.6%$6.00+500.0%-20.8%$290.16M$4.05M-5.0080News CoverageALDXAldeyra Therapeutics1.9186 of 5 stars$5.08+5.6%$9.50+87.0%+12.8%$288.10MN/A-5.2410News CoverageEarnings ReportInsider TradeAnalyst RevisionBNTCBenitec Biopharma1.4688 of 5 stars$11.62+6.0%$26.00+123.8%+38.6%$287.70M$80K-7.7020News CoverageTNXPTonix Pharmaceuticals2.4403 of 5 stars$44.64+14.4%$70.00+56.8%+16.7%$287M$10.09M-0.0250News CoverageEarnings ReportUpcoming EarningsCRVSCorvus Pharmaceuticals2.6336 of 5 stars$4.31+5.1%$15.00+248.0%+22.3%$279.49MN/A-4.4030News CoverageEarnings ReportAnalyst RevisionFHTXFoghorn Therapeutics3.2918 of 5 stars$5.14+3.0%$12.13+135.9%-12.6%$278.15M$22.60M-3.78120TLSATiziana Life Sciences0.7763 of 5 stars$2.45+2.9%N/A+53.1%$278.10MN/A0.008ESPREsperion Therapeutics4.269 of 5 stars$1.49+6.4%$7.00+369.8%-2.7%$277.48M$332.31M-1.86200Gap UpSCPHscPharmaceuticals4.0401 of 5 stars$5.52+6.8%$14.00+153.6%+8.4%$272.93M$36.33M-2.8930Earnings ReportANNXAnnexon2.4128 of 5 stars$2.53+3.3%$12.50+394.1%-56.5%$268.80MN/A-2.1460Gap Up Related Companies and Tools Related Companies Ocugen Alternatives Aldeyra Therapeutics Alternatives Benitec Biopharma Alternatives Tonix Pharmaceuticals Alternatives Corvus Pharmaceuticals Alternatives Foghorn Therapeutics Alternatives Tiziana Life Sciences Alternatives Esperion Therapeutics Alternatives scPharmaceuticals Alternatives Annexon Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMVP) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMV Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMV Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access